BR112018074985A2 - composições antibacterianas - Google Patents

composições antibacterianas

Info

Publication number
BR112018074985A2
BR112018074985A2 BR112018074985-0A BR112018074985A BR112018074985A2 BR 112018074985 A2 BR112018074985 A2 BR 112018074985A2 BR 112018074985 A BR112018074985 A BR 112018074985A BR 112018074985 A2 BR112018074985 A2 BR 112018074985A2
Authority
BR
Brazil
Prior art keywords
antibacterial compositions
pharmaceutically acceptable
acceptable salt
beta
compound
Prior art date
Application number
BR112018074985-0A
Other languages
English (en)
Inventor
Subhash Bhagwat Sachin
Vithalbhai Patel Mahesh
Vitthalrao Deshmukh Vikas
Original Assignee
Wockhardt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Limited filed Critical Wockhardt Limited
Publication of BR112018074985A2 publication Critical patent/BR112018074985A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composição farmacêutica compreendendo inibidores de beta-lactamase ou a sal farmaceuticamente aceitável, e um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo são revelados.
BR112018074985-0A 2016-06-17 2017-06-16 composições antibacterianas BR112018074985A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201621020848 2016-06-17
IN201621020849 2016-06-17
IN201621020849 2016-06-17
IN201621020848 2016-06-17
PCT/IB2017/053587 WO2017216765A1 (en) 2016-06-17 2017-06-16 Antibacterial compositions

Publications (1)

Publication Number Publication Date
BR112018074985A2 true BR112018074985A2 (pt) 2019-03-12

Family

ID=59276797

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074985-0A BR112018074985A2 (pt) 2016-06-17 2017-06-16 composições antibacterianas

Country Status (6)

Country Link
US (1) US20200316083A1 (pt)
EP (1) EP3471724A1 (pt)
CN (1) CN109310682A (pt)
BR (1) BR112018074985A2 (pt)
MX (1) MX2018014813A (pt)
WO (1) WO2017216765A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018193369A1 (en) * 2017-04-18 2018-10-25 Wockhardt Limited Antibacterial compositions
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
WO2020184399A1 (ja) * 2019-03-08 2020-09-17 塩野義製薬株式会社 抗菌用医薬組成物
TW202123945A (zh) * 2019-09-13 2021-07-01 日商鹽野義製藥股份有限公司 具有抗菌作用的醫藥組成物
WO2021147986A1 (zh) 2020-01-22 2021-07-29 上海森辉医药有限公司 头孢类抗菌化合物及其在医药上的应用
TW202241913A (zh) 2021-01-12 2022-11-01 大陸商上海森輝醫藥有限公司 一種頭孢類抗菌化合物及其製備方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341053B1 (en) * 2008-10-31 2016-01-13 Shionogi&Co., Ltd. Cephalosporin having catechol group
RU2684112C2 (ru) * 2013-02-06 2019-04-04 Пфайзер Анти-Инфективз Аб Комбинированная терапия для лечения нозокомиальной пневмонии
MX2016005161A (es) * 2013-10-22 2016-10-05 Wockhardt Ltd Composiciones farmaceuticas que comprenden agentes antibacterianos.
EP3074014A1 (en) * 2013-11-26 2016-10-05 Wockhardt Limited Antibacterial compositions
WO2015125031A1 (en) * 2014-02-20 2015-08-27 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
BR112017004166B1 (pt) * 2014-09-04 2022-11-29 Shionogi & Co., Ltd Sal de derivado de cefalosporina e seu hidratado, sólido cristalino dos mesmos, seu processo de preparação, composição farmacêutica e método para preparar uma formulação liofilizada

Also Published As

Publication number Publication date
MX2018014813A (es) 2019-03-14
WO2017216765A1 (en) 2017-12-21
CN109310682A (zh) 2019-02-05
US20200316083A1 (en) 2020-10-08
EP3471724A1 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
BR112018074985A2 (pt) composições antibacterianas
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
NZ763551A (en) Compounds useful for inhibiting cdk7
PH12016501813B1 (en) 1,3-benzodioxole derivative
TW201613911A (en) Heterocyclic compounds and uses thereof
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
WO2016100578A3 (en) Antimicrobial polymyxins for treatment of bacterial infections
EA201892822A1 (ru) Новые антибактериальные соединения
EA201891644A1 (ru) Антибактериальные соединения и их применение
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
MD3347360T2 (ro) Compuși utili pentru inhibarea ROR-gama-t
WO2018039077A8 (en) Therapeutic compounds
EA201990952A1 (ru) ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met
EA201890412A1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
EA201992370A1 (ru) Соединения и способы для лечения бактериальных инфекций
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
MY182634A (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
GEP20247590B (en) Antibacterial quinolines

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2675 DE 12-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.